Figure 3.
Protein validation of top differential expression results. (A) PAX5, TLR3, and RELB/p100 blots after 72-hour AZD5153 and acalabrutinib treatment. (B) Proteins of the PAX5 transcription factor direct binding targets after overnight drug treatment. (C) Representative images of PAX5 immunofluorescence (top) and quantification of nuclei detection of PAX5 and LEF1 (bottom) after a 72 hour treatment with 20 nM AZD5153, 10 nM acalabrutinib, or a combination. (D) PAX5 knockout in TMD8 cells. Cell viability was measured using CellTiterGlo after 7-day treatment with acalabrutinib. Error bars represent SEM; n = 6. (E) Immunoblot of PAX5 and related proteins from LY6934 tumor lysates after 5-day treatment. PAX5 quantification is normalized to GAPDH. ∗, #, and ## denote P < .05 for comparisons of the control, acalabrutinib, and AZD5153, respectively.

Protein validation of top differential expression results. (A) PAX5, TLR3, and RELB/p100 blots after 72-hour AZD5153 and acalabrutinib treatment. (B) Proteins of the PAX5 transcription factor direct binding targets after overnight drug treatment. (C) Representative images of PAX5 immunofluorescence (top) and quantification of nuclei detection of PAX5 and LEF1 (bottom) after a 72 hour treatment with 20 nM AZD5153, 10 nM acalabrutinib, or a combination. (D) PAX5 knockout in TMD8 cells. Cell viability was measured using CellTiterGlo after 7-day treatment with acalabrutinib. Error bars represent SEM; n = 6. (E) Immunoblot of PAX5 and related proteins from LY6934 tumor lysates after 5-day treatment. PAX5 quantification is normalized to GAPDH. ∗, #, and ## denote P < .05 for comparisons of the control, acalabrutinib, and AZD5153, respectively.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal